Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program

Michael Bilous · Adrienne L. Morey · Jane E. Armes · Richard Bell · Peter H. Button · Margaret C. Cummings · Stephen B. Fox · Glenn D. Francis · Brigid Waite · Glenda McCue · Wendy A. Raymond · Peter D. Robbins · Gelareh Farshid

Received: 27 April 2012 / Accepted: 4 May 2012 / Published online: 8 June 2012 © The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract In August 2006, the Australian government approved subsidized trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, and it was mandated that HER2 testing should be performed using in situ hybridization (ISH) rather than immunohistochemistry (IHC). Here we review results of the first regulated, nationwide program to provide HER2 ISH testing for all newly diagnosed breast cancer patients, with a particular emphasis on cases where IHC and ISH results were discordant. Data from all laboratories participating in the program were collated. Cases with an equivocal ISH test result [by chromogenic ISH (CISH) or silver ISH (SISH)] were tested centrally by fluorescence ISH. Most laboratories also performed HER2 IHC, and 200 cases with discordant IHC and ISH results were selected for further analysis in a central laboratory. A total of 26 laboratories were involved and 53,402 tests were reported. Over a 4-year period the HER2 positivity rate decreased for primary cancers from 23.8 to 14.6 %, but remained

Declaration The authors declare that the experiments described comply with the current laws of Australia.

M. Bilous Healthscope Pathology, The Norwest Private Hospital, Bella Vista, Sydney, NSW 2153, Australia e-mail: Michael.Bilous@healthscope.com.au

M. Bilous ICPMR Westmead Hospital and The University of Sydney, Sydney, NSW 2145, Australia

A. L. Morey Sydpath, St Vincent’s Hospital, Sydney, NSW 2010, Australia

J. E. Armes Anatomical Pathology, Mater Health Services, South Brisbane, QLD 4011, Australia

R. Bell The Andrew Love Cancer Centre, 70 Swanston Street, Geelong, VIC 3250, Australia

P. H. Button Infopeople Pty Limited, Mezzanine Level, 383 Kent Street, Sydney, NSW 2000, Australia

M. C. Cummings University of Queensland Centre for Clinical Research and Pathology Queensland, Royal Brisbane and Women’s Hospital, Herston, QLD 4029, Australia

S. B. Fox The Peter MacCallum Cancer Centre and the University of Melbourne, St Andrews Place, East Melbourne, VIC 3002, Australia

G. D. Francis Pathology Queensland, Herston Hospitals Campus, Royal Brisbane and Women’s Hospital, Herston Rd, Herston, QLD 4029, Australia

G. D. Francis Molecular and Clinical Pathology Research Laboratory, Princess Alexandra Hospital, Ipswich Rd, Woolloongabba, QLD 4102, Australia

G. D. Francis Griffith University, Gold Coast, QLD, Australia

G. D. Francis University of Queensland, St Lucia, QLD 4222, Australia

B. Waite Roche Products Pty Limited, 4–10 Inman Road, Dee Why, NSW 2099, Australia

G. McCue Woolomin Consulting, “Woolomin”, 2535 Sapphire Road, Wheeo, NSW 2583, Australia
relatively constant for samples from metastases. Average ISH reporting times were <5 days for all yearly reporting periods. Test-repeat rates decreased for CISH (8.9–3.6 %) and SISH (13.7–8.4 %). Only 12 of 196 cases remained discordant after retesting in a central laboratory. These findings demonstrate the successful implementation of a regulated, national program that continues to collect data on HER2 status. The results also highlight the differences in IHC interpretation between local laboratories and a central, more experienced, laboratory. This model could be used to establish future biomarker-testing programs in other countries.

**Keywords**  Breast cancer · HER2 Genes · In situ hybridization · Immunohistochemistry

**Abbreviations**

- amp: Amplification
- ASCO: American Society of Clinical Oncology
- CAP: College of American Pathologists
- CEP17: Chromosome enumeration probe 17
- Chr: Chromosome
- CISH: Chromogenic in situ hybridization
- EBC: Early breast cancer
- FISH or (f): Fluorescence in situ hybridization
- HER2: Human epidermal growth factor receptor 2
- IHC: Immunohistochemistry
- ISH: In situ hybridization
- MBC: Metastatic breast cancer
- SISH or (s): Silver in situ hybridization

**Introduction**

The human epidermal growth factor receptor 2 (HER2) gene is amplified in ~15–20 % of breast cancers and has been linked with poor prognosis [1–6], making it an attractive molecular target for breast cancer therapy.

Trastuzumab (Herceptin®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) is an anti-HER2 monoclonal antibody with proven survival benefits in the treatment of women with HER2-positive metastatic breast cancer (MBC) [7–11] and early breast cancer (EBC) [12–15]. Evaluation of the HER2 status of all breast cancers at diagnosis is recommended to predict the potential benefit from trastuzumab treatment [16, 17].

HER2 testing is performed by either immunohistochemistry (IHC) or in situ hybridization (ISH). IHC uses anti-HER2 antibodies to detect HER2 protein expression levels, and is assessed semiquantitatively by the proportion and intensity of staining. ISH uses DNA probes to determine HER2 gene copy number. To ensure accurate HER2 testing, as well as consistent and appropriate patient selection for trastuzumab therapy, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) convened an expert panel to compile and publish HER2 testing recommendations that included an algorithm to define positive, negative, and equivocal HER2 results according to both HER2 protein expression and gene amplification [18]. According to the ASCO/CAP guidelines, a HER2-positive result by IHC is uniform, intense staining of >30 % of invasive tumor cells (3+) and a positive result by ISH is >6 HER2 gene copies per nucleus or a HER2 gene:chromosome enumeration probe 17 (CEP17) signal ratio of >2.2 [18].

A minority of the ASCO/CAP panel expressed the view that IHC is not a sufficiently accurate assay to determine HER2 status [18], and two large trials have shown discordance between local and central HER2 testing by IHC [19] or by both IHC and fluorescence ISH (FISH) [20]. Analysis of concordance between a local and a high-volume central laboratory in a phase IV trial [21] also showed poor concordance of IHC results, and concluded that HER2 testing is most accurate when performed at a high-volume central laboratory.

In Australia, ~14,000 new breast cancer cases are diagnosed annually [22]. Patients with HER2-positive MBC, determined by either IHC or ISH, are eligible for trastuzumab therapy as part of the Herceptin program administered by Medicare Australia. Patients with HER2-positive EBC are also eligible for trastuzumab therapy under the Australian government-funded Pharmaceutical Benefits Scheme. The Pharmaceutical Benefits Advisory Committee specified that HER2 positivity should be demonstrated by ISH in these patients. This requirement led to the development of the Australian In Situ Hybridization Program, a nationwide program utilizing ISH as the HER2 testing platform. The program was launched as a multi-center, coordinated project, with the primary objective being to provide accurate tumor ISH testing for all patients diagnosed with EBC. Accurate testing is critical in guiding...
the provision of trastuzumab therapy to those who are likely to derive the most benefit from the treatment.

Here, we include details of the HER2 positivity rates recorded across Australia from October 2006 to September 2010 for patients with EBC or MBC, along with other test-related data; including result turnaround times and repeat testing rates. Most laboratories continue to use IHC in parallel with ISH and we also document the results of a reevaluation of 200 samples that had shown discordance between local IHC results and ISH results from a central reference laboratory.

Methods

Study design

The Australian In Situ Hybridization Program is a nationwide, multicenter, coordinated project sponsored by Roche Products Pty Limited (Dee Why, Australia) and overseen by the Australian HER2 Testing Advisory Board. Details of establishing of this program, including identification, training, certification, and accreditation of all laboratories, as well as the implementation of standardized reporting protocols, have been described previously [22].

Sample selection

The majority of samples for HER2 ISH testing were from excised tumors from women aged ≥18 years with EBC or MBC. Approximately 10% of samples were core biopsies and <1% were from fine needle aspiration cell block material, or from male breast cancer patients.

HER2 testing

All local laboratories were responsible for the provision of an accurate and timely HER2 testing service to support clinical decision-making in their area. Figure 1 shows the ISH assay algorithm used to determine HER2 positivity. A validated single-probe ISH test was used for all samples, with a CEP17 probe used for equivocal cases, defined as 4–6 HER2 signals per nucleus. Cases that remained equivocal following dual-probe testing (defined as a HER2:CEP17 ratio of 1.8–2.2) or which were non-diagnostic due to a weak signal, were sent to a central reference laboratory for FISH testing using the PathVysion® kit (Vysis/Abbott, Illinois, USA). IHC was used in conjunction with ISH as a quality control, both to assess tumor heterogeneity and to assist in the overall assessment of difficult-to-assess cases. In the initial phase of the program, IHC was used by some laboratories lacking the facility to perform ISH, to triage cases to be sent for ISH testing at one of the program laboratories. This practice gradually diminished over time, such that the vast majority of invasive cancer cases were submitted for ISH testing regardless of whether IHC had been performed, or of the IHC result.

All laboratories initially used a chromogenic ISH kit (CISH; SpO-1Light® CISH, Invitrogen, California, USA). Approximately 1 year after the launch of the program, silver ISH (SISH; Inform™, Ventana Medical Systems, Inc., Arizona, USA) was also included as an alternative ISH testing assay, with a third option (DuoCISH™, Dako, Glostrup, Denmark) included 6 months later. All kits were used in accordance with the ISH assay algorithm (Fig. 1) and, from March 2008, the scoring of all HER2 tests adhered to the 2007 ASCO/CAP recommendations [18].

Data collection

All HER2 test results, reporting times, test-repeat rates, and the proportion of tests performed on core biopsies were recorded. Means of each parameter were calculated for each laboratory and state during the measurement periods of October–September for 2006–2007, 2007–2008, 2008–2009, and 2009–2010. Mean HER2 positivity rates were also calculated for each laboratory and state for the four 12-month time periods.

Comparison of IHC and ISH results

Two hundred invasive carcinomas were selected from patients, in which IHC had been performed at a local laboratory and the paraffin blocks or unstained sections had been forwarded to a central reference laboratory for ISH testing. All selected cases had shown discordance between local IHC and central ISH results. The cases included were
either IHC 0/IHC 1+ that showed HER2 gene amplification (false-negative, \( n = 31 \)) or IHC 3+ that showed no HER2 gene amplification (false-positive, \( n = 169 \)). The central laboratory performed IHC on archived, unstained sections from all the cases using the 4B5 antibody (Ventana Medical Systems, Inc.) on the Ventana BenchMark Immunostainer (Ventana Medical Systems, Inc.). The stained slides were then assessed by a pathologist blinded to both the original IHC result, and to the HER2 gene amplification status. In cases of uncertainty a second pathologist independently assessed the slide and, if necessary, the case was viewed by both pathologists together and a consensus score reached.

**Results**

**HER2 positivity rates**

By September 2010, the Australian In Situ Hybridization Program had been running for 4 years and had performed 53,402 ISH tests. Overall, 26 laboratories were approved for ISH testing. In the final reporting period, eight laboratories used CISH and 18 used SISH assays.

The total number of ISH tests conducted between October 2006 and September 2010, as well as the HER2 positivity rates for samples from EBC and MBC, are shown in Tables 1 and 2. Between October 2006 and September 2010, the overall HER2 ISH positivity rate was 16.9% for EBC and 22.5% for MBC. The HER2 positivity rate for EBC decreased each year from 23.8% in the first 12-month period to 14.6% in the final 12 months, whereas the MBC HER2 positivity rate varied from 22.6% in the first 12 months, from 1.6 to 10.5 days in the second 12 months, from 1.0 to 10.2 days in the third 12 months, and from 1.3 to 10.9 days in the final 12 months. Average reporting times were longer than 7 days for 2 out of 17, 4 out of 20, 6 out of 26, and 4 out of 26 laboratories for the four consecutive reporting periods.

ISH test-repeat rates for each laboratory are shown in Table 3. In the first 12 months the overall ISH test-repeat rate was 8.9%, decreasing to 8.2% in the second 12 months for laboratories using CISH. Twelve laboratories changed from using CISH to SISH in the second 12-month period. Repeat rates were higher (13.7%) in these laboratories, although this was primarily caused by a global silver wash contamination issue that was subsequently addressed and resolved. In the third 12-month reporting period, test-repeat rates were 4.9% for laboratories using CISH and 7.2% for laboratories using SISH.

Table 1 HER2 positivity rates by ISH in early breast cancer tissue samples

| State                    | October 2006 –September 2007 | October 2007–September 2008 | October 2008–September 2009 | October 2009–September 2010 |
|--------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
|                          | Total cases, \( n \) | ISH-positive, \( n \) (\%) | Total cases, \( n \) | ISH-positive, \( n \) (\%) | Total cases, \( n \) | ISH-positive, \( n \) (\%) | Total cases, \( n \) | ISH-positive, \( n \) (\%) |
| Australian Capital Territory | 208 | 34 (16.3) | 310 | 54 (17.4) | 352 | 67 (19.0) | 371 | 53 (14.3) |
| New South Wales          | 3,424 | 989 (28.9) | 5,025 | 995 (19.8) | 6,067 | 1,021 (16.8) | 6,076 | 870 (14.3) |
| Queensland               | 1,423 | 356 (25.0) | 2,205 | 330 (14.9) | 2,811 | 410 (14.6) | 3,151 | 468 (14.9) |
| South Australia          | 827 | 124 (15.0) | 1,060 | 153 (14.4) | 1,254 | 181 (14.4) | 1,247 | 147 (11.8) |
| Victoria                 | 1,478 | 306 (20.7) | 2,391 | 360 (15.1) | 2,751 | 464 (16.9) | 3,879 | 660 (17.0) |
| Western Australia        | 475 | 56 (11.8) | 704 | 86 (12.2) | 1,455 | 181 (12.4) | 1,571 | 176 (11.2) |
| Tasmania                 | – | – | 88 | 11 (12.5) | 312 | 48 (15.4) | 292 | 51 (17.5) |
| Northern Territory\(^a\) | – | – | – | – | – | – | – |
| Total                    | 7,835 | 1,865 (23.8) | 11,783 | 1,989 (16.8) | 15,002 | 2,372 (15.8) | 16,587 | 2,425 (14.6) |

Results from states across Australia recorded over time

HER2 human epidermal growth factor receptor 2, ISH in situ hybridization

\(^a\) Northern Territory cases were tested at an ISH reference laboratory in New South Wales
In the final reporting period, test-repeat rates were 3.6% for laboratories using CISH and 8.4% for laboratories using SISH.

Retesting of discordant IHC/ISH cases

Of the 200 discordant cases selected, four were considered unsuitable for assessment due to the presence of considerable artifact(s), insufficient tissue, or loss or damage to the section during processing. Of the remaining 196 cases retested by IHC, 184 (94%) showed concordance between the results of the repeat IHC and ISH. Eleven of the 12 cases that remained discordant (91.6%) were false-negative and one was false-positive. The details of these 12 cases are shown in Table 4.

An analysis of the cases that were now concordant following retesting showed that there were 45 cases reclassified from IHC 3+ to IHC 2+ (equivocal). Of those, 14 (31%) had a chromosome 17 polysomy. Of the 161 cases that were originally scored as IHC 3+ but did not show gene amplification by ISH, 116 (72%) were scored as IHC 0 or IHC 1+ after retesting.

Discussion

Since the inception of the Australian In Situ Hybridization Program in October 2006, the number of HER2 ISH tests has increased each year; reflecting a shift toward HER2 ISH testing of all breast cancer samples (rather than the previous practice of triaging samples for ISH testing on the basis of IHC results). There was a 112% increase in ISH testing reported between the first and last time period for patients with EBC, which is attributable to a greater understanding of the ISH testing program (i.e., all patients should be tested for ISH, regardless of IHC results), laboratory implementation of the ISH testing algorithm, and an increased number of laboratories qualified to report ISH. In addition, there is greater awareness among oncologists and breast surgeons that trastuzumab therapy should be available to all EBC patients with a positive ISH result. By comparison, ISH reporting of MBC cases was low and increased by just 20% between the first and last reporting periods. Initial ISH testing of MBC cases is not a requirement of the Herceptin program administered by Medicare Australia. The smaller increase observed, may also reflect the fact that many patients presenting with MBC could have previously had their primary tumor tested for HER2 and therefore, may have received trastuzumab in the adjuvant setting [23]. In patients with EBC there was a reduction in HER2 positivity rates reported between the time periods (from 23.8 to 14.6%) which reflects a shift toward the use of ISH testing for all samples without prior IHC triaging. The HER2 positivity rate of 14.6% is comparable to rates reported in the literature [2–6, 24]. Although the average HER2 positivity rate among patients with MBC was higher than for EBC for all time periods and showed variations across the reporting period (22.6, 25.1, 21.3, and 21.6% for the first, second, third, and fourth 12-month periods, respectively), these rates were also similar to those reported in the literature [2–6, 25, 26], suggesting that MBC is associated with a higher HER2 positivity rate than EBC and reflecting a more aggressive tumor cohort.
The decision to make trastuzumab therapy available to patients with HER2-positive EBC following an ISH-positive test is supported by recent guidelines for HER2 testing [27], which favor ISH over IHC due to its greater test accuracy, objectivity, and reproducibility. However, it should be noted that the use of ISH testing alone is associated with some risks, including an increased likelihood of failing to detect heterogeneity, overscoring highly polysomic cases (when a single probe is used), and missing cases with low HER2 amplification. IHC is, therefore, a valuable tool for the assessment of equivocal or difficult cases and remains an important quality assurance measure. As such, we feel that the use of ISH testing, together with additional IHC testing as required, ensures the provision of accurate testing by all local laboratories, with a central laboratory providing further evaluation by FISH as necessary.

The efficiency of all laboratories involved in this nationwide program was illustrated by the consistently short overall reporting time for ISH tests, with average reporting times reduced slightly in the second 12-month period, despite the inclusion of four new laboratories and the fact that 12 laboratories switched to SISH testing. Average reporting times remained consistent in the third and fourth 12-month periods (4.6 and 4.5 days, respectively). For those laboratories that continued to use CISH, the test-repeat rates also decreased over the reporting period, reflecting the improvements in testing proficiency as a result of increasing experience. In the second reporting period, test-repeat rates were higher than expected for laboratories using SISH (13.7 %); however, this was attributed to a contamination of the silver wash which was reported in a number of countries outside Australia, and the test-repeat rate fell during the final two reporting periods to 7.2 and 8.4 %, respectively.

This study has demonstrated that there are inherent inaccuracies in local laboratory staining and/or assessment of HER2 IHC, where ISH is considered the “gold standard” test. This is highlighted by the fact that 72% of the 161 cases originally scored as IHC 3+ by local laboratories but found to be non-amplified by ISH were subsequently scored as IHC 0 or IHC 1+ by a central laboratory. However, our study has shown that very good concordance (94%) exists between IHC and ISH when both tests are performed and interpreted by experienced laboratories and pathologists. There were a range of factors contributing to the discordance in the remaining 12 cases, including monosomy of chromosome 17 (three cases), and clonal amplification of HER2 (one case). All of these cases showed only a low level amplification of the HER2 gene (HER2:CEP17 ratio range 2.3–5.48). There is some debate regarding the relative importance of HER2:CEP17 ratio versus HER2 copy number in assessing ISH [28, 29] and there was discordance between the two methods in 6/12 of our cases, reflecting the lack of an IHC 3+ score.

Although IHC/ISH discordance has been demonstrated previously in the setting of some clinical trials involving centralized retesting by FISH [20], our study has focused specifically on discordant cases. It remains unclear whether the laboratory test procedure, the pathologist’s interpretation, or both, contribute to the observed discordances. Therefore, a valuable additional analysis will be to compare results from small- and large-testing volume laboratories; however, this was not possible with the existing data.

The emphasis on accurate HER2 testing has been highlighted by the ASCO/CAP expert panel [18]. As well as recommending an updated scoring system for HER2 assessment, multiple factors that can cause variation in HER2 testing accuracy were identified, including fixation

| Laboratory ID | Average ISH test-repeat rate, % | October 2006–September 2007 | October 2007–September 2008 | October 2008–September 2009 | October 2009–September 2010 |
|---------------|--------------------------------|-----------------------------|----------------------------|-----------------------------|-----------------------------|
| 1a            | 6.6                            | 22.2                        | 20.2                       | 13.7                        |
| 2             | –                              | –                           | 1.8                        | 5.2                         |
| 3             | 9.0                            | 6.6                         | 6.3                        | 0.0                         |
| 4a            | –                              | 13.2                        | 10.8                       | 5.2                         |
| 5a            | 6.7                            | 3.7                         | 3.5                        | 8.4                         |
| 6             | 2.0                            | 1.6                         | 0.7                        | 0.8                         |
| 7a            | –                              | –                           | 0.0                        | 4.5                         |
| 8a            | –                              | 10.5                        | 1.4                        | 3.4                         |
| 9a            | –                              | 6.5                         | 6.8                        | 6.6                         |
| 10a           | 8.4                            | 18.7                        | 22.7                       | 26.8                        |
| 11a           | 4.4                            | 3.9                         | 4.9                        | 6.4                         |
| 12a           | 16.8                           | 14.7                        | 6.1                        | 13.5                        |
| 13a           | 5.9                            | 4.6                         | 8.4                        | 4.9                         |
| 14a           | 8.7                            | 8.8                         | 3.1                        | 9.4                         |
| 15a           | 10.2                           | 12.4                        | 11.2                       | 0.5                         |
| 16            | –                              | –                           | 1.1                        | 7.7                         |
| 17            | –                              | –                           | 0.0                        | 4.1                         |
| 18a           | 5.5                            | 4.2                         | 2.9                        | 7.8                         |
| 19            | 23.5                           | 14.3                        | 5.0                        | 2.1                         |
| 20a           | 9.0                            | 15.4                        | 5.7                        | 10.7                        |
| 21            | 5.3                            | 4.2                         | 4.9                        | 6.1                         |
| 22a           | 15.9                           | 13.7                        | 5.9                        | 2.1                         |
| 23a           | 6.0                            | 11.2                        | 10.0                       | 5.7                         |
| 24            | 5.8                            | 7.3                         | 2.6                        | 2.8                         |
| 25a           | 10.6                           | 11.5                        | 4.1                        | 0.4                         |
| 26a           | –                              | 37.0                        | 9.5                        | 21.1                        |

ISH in situ hybridization

a Laboratories using silver ISH for the final reporting period
methods and assay reagents used [18]. Several standard
assays exist for HER2 testing, which could result in a high
degree of testing inaccuracy. The Australian In Situ
Hybridization Program, as well as adhering to the ASCO/
CAP HER2 testing guidelines, uses standardized HER2
testing kits (CISH, SISH, or DuoCISH) to minimize
interlaboratory variation. All pathologists participating in
the Australian In Situ Hybridization Program are required
to perform a minimum number of 50 ISH tests annually,
and each laboratory must perform a minimum of 150 tests
annually. This ensures that there is a sufficient level of
experience in participating laboratories. Participation in
appropriate quality assurance programs is also mandatory.
Further efforts to ensure the implementation of a highly
accurate and robust HER2 testing system as part of this
nationwide program included the emphasis on testing the
excised tumor wherever possible, as testing on core bi-
opisies may be less reliable [30]. Our data indicate that core
biopsies were used for HER2 testing in <10% of cases in
most laboratories.

In summary, these findings demonstrate the successful
implementation of a regulated, nationwide testing program
that continues to collect data on HER2 testing in patients
with breast cancer. We feel that the implementation of a
high standard of training, accreditation, and quality assur-
ance, as well as a streamlined approach to testing and
reporting, have been fundamental to the success of this
program. This methodology could be used as a model for
the establishment of HER2 testing in other countries or for
the implementation of other new biomarker-testing
initiatives.

Table 4 Results of the 12 immunohistochemistry/in situ
hybridization discordant cases

| Case number | Local IHC | Central IHC | HER2 gene copy number | HER2:CEP17 ratio | Comments |
|-------------|-----------|-------------|-----------------------|------------------|----------|
| 1           | 1+        | 1+          | 5.8 (f)               | 4.46             | Low amp b |
| 2           | 1+        | 1+          | 7.75 (f)              | 2.87             | Low amp   |
| 3           | 1+        | 1+          | 8.15 (s)              | Not done         | Low amp   |
| 4           | 0         | 1+          | 7.35 and 1.25 (f)     | 2.94 and 1.9     | Low amp Clonal |
| 5           | 1+        | 0           | 6.15 (f)              | 2.3              | Low amp   |
| 6           | 1+        | 1+          | 7.75 (f)              | 4.31             | Low amp   |
| 7           | 1+        | 1+          | 4.55 (f)              | 2.52             | Low amp Clonal |
| 8           | 1+        | 1+          | 2.92 (f)              | 2.7              | Low amp Clonal |
| 9           | 1+        | 1+          | 3.95 (f)              | 2.47             | Low amp Clonal |
| 10          | 1+        | 1+          | 5.75 (f)              | 5.48             | Low amp Clonal |
| 11          | 1+        | 0           | 4.9 (f)               | 2.97             | Low amp Clonal |
| 12          | 3+        | 3+          | 1.7 (f)               | 0.92             | Non amp   |

Acknowledgments The sponsor of this study was Roche Products
Pty Limited, Dee Why, New South Wales, Australia.
Support for third-party writing assistance for this manuscript was
provided by F. Hoffmann-La Roche Ltd.

Conflict of interest Michael Bilous has held a consultant/advisory
role with F. Hoffmann-La Roche Pty Ltd. Adrienne L. Morey,
Richard Bell, and Stephen B. Fox have held consultant/advisory roles
with Roche. Adrienne L. Morey has held a consultant/advisory role with
Pfizer. Jane E. Armes has held a consultant/advisory role with the
HER2 Testing Advisory Committee. Glenn D. Francis has held
consultant/advisory roles with Roche Pharmaceuticals, Roche Ven-
tana Medical Systems, Merck Serano, and Astra Zeneca. Brigid Waite
is an employee of Roche Products Pty Ltd. Glenda McCue has held a
consultant/advisory role with Woolomin Consulting. Gelareh Farshid
has held a consultant/advisory role with the Australian HER2 Advi-
sory Board. Peter H. Button, Margaret C. Cummings, Wendy A.
Raymond, and Peter D. Robbins have no conflict of interest to
disclose.

Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.

References

1. Francis GD, Jones MA, Beadle GF et al (2009) Bright-field in situ
hybridization for HER2 gene amplification in breast cancer using
tissue microarrays: correlation between chromogenic (CISH) and
automated silver-enhanced (SISH) methods with patient outcome.
Diagn Mol Pathol 18:88–95
2. Gown AM, Goldstein LC, Barry TS et al (2008) High concor-
dance between immunohistochemistry and fluorescence in situ
hybridization testing for HER2 status in breast cancer requires a
normalized IHC scoring system. Mod Pathol 21:1271–1277
3. Press MF, Sauter G, Bernstein L et al (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598–6607
4. Owens MA, Horten BC, Da Silva MM (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5:63–69
5. Konecný G, Pauletti G, Pegram M et al (2003) Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95:142–153
6. Penault-Llorca F, Ettore F, Antoine M et al (2006) Comparison of immuno-histochemistry and fluorescence in situ hybridisation techniques for determination of the HER2 gene status of patients with metastatic breast cancer in France: final results of the FISH 2002 study. Poster 5016 presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, 14–17 Dec 2006
7. Baselga J, Carbonell X, Castañeda-Soto N-J et al (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23:2162–2171
8. Eiermann W, on behalf of the International Herceptin Study Group (2001) Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol 12(suppl 1):S57–S62
9. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2—positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265–4274
10. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792
11. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726
12. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809–820
13. Perez EA, Romond VH, Suman VJ et al (2007) Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol (Meeting Abstracts) 25(suppl 6):512
14. Slamon D, Eiermann W, Robert N et al (2006) Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis. Oral presentation at the 29th San Antonio Breast Cancer Symposium, San Antonio, 14–17 Dec 2006
15. Smith I, Proctor M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29–36
16. National Comprehensive Cancer Network (2010) NCCN clinical practice guidelines in oncology: breast cancer V.1.2012. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf
17. Bast RC Jr, Ravdin P, Hayes DF et al (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865–1878
18. Wolff AC, Hammond MEH, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145
19. Paik S, Bryant J, Tan-Chiu E et al (2002) Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852–854
20. Perez EA, Suman VJ, Davidson NE et al (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032–3038
21. Reddy JC, Reimann JD, Anderson SM et al (2006) Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer 7:153–157
22. Farshid G, Armes JE, Bell R et al (2010) Establishment of Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice. Diagn Mol Pathol 19:187–193
23. Weisgerber-Kriegl U, Cirrincione A, McNiven P (2008) Estimation of the epidemiological effect of trastuzumab over 10 years in 5 European countries. Poster 6589 presented at the 44th ASCO Annual Meeting, Chicago, 30–3 May–June 2008
24. Yaziji H, Goldstein LC, Barry TS et al (2004) HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291:1972–1977
25. Cabiochlu N, Sahin AA, Morandi P et al (2009) Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 20:1013–1019
26. Emi Y, Kitamura K, Shikada Y et al (2002) Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis. Surgery 131(Suppl 1):S217–S221
27. Sauter G, Lee J, Bartlett JM et al (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323–1333
28. Vranic S, Teruya B, Repertinger S et al (2011) Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 117:48–53
29. Perez EA, Reinholz MM, Hillman DW et al (2010) HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 28:4307–4315
30. Shousha S, Peston D, Amo-Takyi B et al (2009) Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 54:248–253
